Fernández-Noyola G, Martínez JÁ, Ahumada-Tamayo S, Santana-Ríos Z, Urdiales-Ortiz A, Fulda-Graue S, Pérez-Becerra R, Hernández-Castellanos V, Merayo-Chalico C, Saavedra-Briones D, Sánchez-Turati G, Cantellano-Orozco M, Morales-Montor G, Pacheco-Gahbler C

Language: Spanish
References: 13
Page: 207-212
PDF size: 392.74 Kb.

ABSTRACT

Introduction: Prostate cancer is one of the most important and frequent medical problems in the male population in Mexico. Despite the advent and accessibility of prostate specific antigen, approximately 22% of newly diagnosed cases present with metastatic disease. The natural evolution of prostate cancer is characterized by bone metastasis in approximately 65-80% of patients with advanced disease.
Objective: To determine the clinical and pathological characteristics of patients with recent prostate cancer diagnosis managed at the urology department of the Hospital General Dr. Manuel Gea González.
Methods: Retrospective revision of case records of patients diagnosed with prostate cancer at the authors’ institution in the time frame of January 2007 to May 2010 was carried out. Bone scintigraphy with Tc-99m MDP had been done on these patients to determine bone metastatic disease at the time of diagnosis.
Results: A total of 193 clinical case records that met selection criteria were reviewed. Mean age of patients was seventy years. Bone metastases were found in 31.08% of patients. In patients with prostate specific antigen under 10 mg/dL, only two cases presented with bone metastases at the time of diagnosis. In patients with prostate specific antigen between 10-20 mg/dL the figure was 24.1% for bone metastases, and in patients with prostate specific antigen above 20 mg/dL the figure was 34.9%. In patients with Gleason score of 6, seven patients had metastases; with Gleason score of 7, twelve patients had bone metastases; and with Gleason score of 8 or above, 40.5% of patients had bone metastases. In regard to rectal examination, in patients with clinical stage T1c, 24% presented with bone metastases. In patients with clinical stage T2a, 28.2% presented with bone metastases; in patients with stage T2b the figure was 31.9% and in patients with stage T2c, the figure was 35.8%. In patients with clinical stage T3, 54% presented with bone metastases at the time of diagnosis.
Conclusions: Bone metastases present more frequently in patients with prostate specific antigen above 20 mg/dL and uniform Gleason score. However, general metastasis rate was 30.9%.

REFERENCES

1. Registro histopatológico de Neoplasias Malignas de México, 2003.

2. Partin AW, Kattan MW, Subong EN, et al. Combination of prostatespecific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-51.

3. Wolff JM, Zimny M, Borchers H, et al. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol 1998;33:376-81.

4. Carlin BI, Andriole GL. The natural history, skeletal complications and management of bone metastases in patients with prostate carcinoma. Cancer 2000;88(12Suppl):2989-94.

5. Abuzallouf S, Dayes I, Lukka H: Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 2004;171(6Pt1):2122-7.

6. Heidenreich A, Bellmunt J, Bolla M. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71.

7. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) In: http://www.nccn.org/clinical.asp. Fecha de consulta: abril, 7, 2011.

8. Greene FL, Page DL, Fleming ID, et al. American Joint Committee on Cancer staging manual. 6th ed. Philadelphia, PA: Springer; 2002.

9. Salonia A, Gallina A, Camerota TC, et al. Bone metastases are infrequent in patients with newly diagnosed prostate cancer: analysis of their clinical and pathologic features. Urology 2006;68:362-6.

10. Ritenour CW, Abbott JT. Goodman Utilization of Gleason Grade as primary criterion for ordering nuclear bone scan in newly diagnosed prostate cancer patients. Scientific World Journal 2009;9:1040-5.

11. Klatte T, Klatte D, Bohm M, et al. Radionuclide bone scan in patients with newly diagnosed prostate cancer. Clinical aspects and cost analysis. Urologe A 2006;45:1293-4,1296-9.

12. Ishizuka O, Tabane t, Nakayama T, el al. Prostate-specific antigen, Gleason sum and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in Japan. Int J Urol 2005;12:728-32.

13. Brigantti A, Passoni N, Ferrari M, et al. When to perform bone scan in patients newly diagnosed Prostate cancer: External Validation of the Currently Available Guidelines and Proposal of a Novel Risk Stratification Tool. Eur Urol 2010;57:551-8.